Cardiology
BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
Published in Cardiovascular Business Week, March 20th, 2007
BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today pre-clinical data from trials of BL-1040 demonstrating that BL-1040 is effective in preventing deterioration of the myocardium after a myocardial infarction (MI), thereby reducing left ventricle dilatation and eventual heart failure in a pig model. Professor Jonathan Leor, MD, Director of the Neufeld Cardiac Research Institute at Sheba Medical Center in Israel, presented pre-clinical data on BL-1040 at the Cardiovascular Revascularization Therapies (CRT) conference, held March 7-9, 2007 in Washington, D.C.
"We are encouraged by these results, as BL-1040 is the first injectable liquid...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm Stent Graft Market to Grow to $550 Million by 2011 - Angiography
Westside Medical Imaging Announces the Presentation of Their Research Findings at the Annual Society for Cardiovascular Angiography and Interventions Scientific Sessions - Arrhythmia
New Study Finds Commonly Used Heart Monitoring System Often Fails to Detect Serious Cardiac Arrhythmias, a Leading Cause of Stroke and Sudden Cardiac Death - Atherosclerosis Therapy
Research from Wyeth in the area of atherosclerosis therapy published - Cardiology
OSI Systems Announces FDA Clearance for U.S. Sale and Distribution of Diagnostic Cardiology Data Management System - Cardiology
t2cure Founders Honored for Medical Top Science - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
